艾米替诺福韦对CHB患者HBV DNA及不良反应的影响  

The effect of Amitinofovir on HBV DNA and adverse reactions in CHB patients

作　　者：李京平 Li Jingping(Changsha Third Hospital,Changsha,Hunan 410000,China)

机构地区：[1]长沙市第三医院,湖南长沙410000

出　　处：《首都食品与医药》2024年第18期55-57,共3页Capital Food Medicine

摘　　要：目的探究慢性乙型肝炎(CHB)患者疾病干预中艾米替诺福韦对患者乙肝病毒基因(HBV DNA)的影响和产生的不良反应.方法此次研究时间为2023年1月-2023年12月,研究对象为慢性乙型肝炎(CHB)患者,研究数量为86例.分组使用随机数字表法,将研究对象分为观察组、对照组,两组各43例,观察组采用艾米替诺福韦治疗,对照组采用富马酸替诺福韦治疗,对比两组治疗24周和48周时的乙型肝炎表面抗原(hepatitis B surface anti-gen,HBsAg)、谷丙转氨酶(alanine transaminase,ALT)、乙肝病毒基因(hepatitis B virus deoxyribo-nucleic acid,HBV DNA)、治疗效果(内容涵盖显效、有效和无效)、不良反应(内容涵盖恶心、呕吐和口苦等).结果治疗前组间HBsAg、ALT、HBV DNA无显著差异(P>0.05),治疗后24周、48周两组的HBsAg、ALT、HBV DNA均比治疗前低(P<0.05),观察组比对照组更低(P<0.05);观察组治疗效果与对照组相比,无显著差异(P>0.05);观察组不良反应率低于对照组(P<0.05).结论在慢性乙型肝炎(CHB)疾病干预中应用艾米替诺福韦具有显著的价值,能够改善患者肝功能,控制疾病进一步发展,减少患者体内病毒数量,提升患者的机体免疫能力,使用安全性高,能够实现疾病干预的价值.Objective To explore the effect of amitinofovir on hepatitis B virus gene(HBV DNA)and adverse reactions in patients with chronic hepatitis B(CHB)during disease intervention.Methods This study was conducted from January 2023 to December 2023,targeting 86 patients with chronic hepatitis B(CHB).The study was conducted using the digital table method,with 43 cases in each of the observation and control groups.The observation group received treatment with amitripfovir,while the control group received treatment with fumaric acid tenofovir.The observation and control groups were compared for treatment with hepatitis B surface antigen(HBsAg),alanine transaminase(ALT),and Hepatitis B virus deoxyribonucleic acid(HBV DNA),therapeutic effect(including obvious effect,effective and ineffective),adverse reactions(including nausea,vomiting and bitter mouth).Results There was no significant difference in HBsAg,ALT,and HBV DNA between the observation group and the control group before treatment(P>0.05).HBsAg,ALT,and HBV DNA were lower than before treatment at 24 and 48 weeks after treatment(P<0.05),and the observation group was lower than the control group(P<0.05);There was no significant difference in treatment effect between the observation group and the control group(P>0.05);the incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion The use of Amitinofovir in the intervention of chronic hepatitis B(CHB)has significant value,which can improve liver function,control further disease development,reduce the number of viruses in the patient's body,enhance the patient's immune ability,and achieve the value of disease intervention with high safety.

关 键 词：艾米替诺福韦 慢性乙型肝炎 乙肝病毒基因 不良反应 

分 类 号：R512.62[医药卫生—内科学]